Company Information
Industry 制造业
Company Introduction 江苏硕世生物科技股份有限公司(以下简称「硕世生物」,证券代码:688399.SH)创立于2010年,2019年12月正式登陆科创板,是一家集体外诊断产品、医学检验服务、大健康消费医疗于一体的国家高新技术企业、国家级专精特新「小巨人」企业。 作为分子诊断的技术先行者与产业赋能者,硕世生物深耕「传染病检测」和「妇幼健康」领域,自主研发超700种体外诊断试剂及智能自动化设备,构筑了从关键原材料、医学实验室产品到专业化技术服务的全产业链布局,为临床诊断、公共卫生防控、家庭自测等多元化场景提供精准、可靠的全栈式综合解决方案。 公司立足多重荧光PCR、POCT核心平台,加速推进dPCR、质谱及NGS等前沿关键技术的布局和临床转化。依托单平台的纵深拓展与跨平台的协同融合,在深耕传统优势业务的基础上,进一步向疾病极早期识别与全病程管理延伸,构建起覆盖肿瘤早筛、呼吸道感染检测、慢病防控及营养管理的广泛健康生态。 在「可持续发展和全球创新」的战略领航下,硕世生物加速推进全球化布局,以中国香港、印尼、美国和巴西子公司为战略支点,建立本地化运营体系,依托549项国际准入认证,产品已远销全球超100个国家和地区,向「成为世界级精准诊断企业」目标愿景稳步迈进。
Main Business 体外诊断试剂、配套检测仪器等体外诊断产品的研发、生产和销售,并拓展到体外检测服务领域,实现“仪器+试剂+服务”的一体化经营模式。
Legal Representative 王国强
Top Executives
董事长:王国强
名誉董事长:房永生
董事:梁钶承,胡园园,郭海涛,王国强,房永生
独立董事:刘霄仑,高光侠,杨顺海
Top 5 Shareholder
Shareholder name Nature Holding Date
绍兴闰康生物医药股权投资合伙企业(有限合伙)流通A股27.53%30/06/2026
王国强流通A股8.73%30/06/2026
杨世刚流通A股2.33%30/06/2026
泰州硕康企业管理咨询合伙企业(有限合伙)流通A股1.91%30/06/2026
泰州硕源企业管理咨询合伙企业(有限合伙)流通A股1.91%30/06/2026
Company Secretary 胡园园
Solicitors 上海市通力律师事务所
Auditors 立信会计师事务所(特殊普通合伙)
Tel No 0523-80225599
Fax No 0523-86201617
Website www.s-sbio.com
Email sssw@s-sbio.com
Company Address
Register: 江苏省泰州市药城大道837号
Office: 江苏省泰州市药城大道837号
Listing Date 05/12/2019
Shares Capital
Shares Capital: 124,130,147
Total A Share: 124,130,147
Listed A Share: 124,130,147
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.490
DPS(RMB)* ¥ 3.400
NBV Per Share(RMB)* ¥ 34.918
Market Capitalization(RMB) 3.503B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.